-
1.发明公开METHOD OF DETECTING POLYMORPHISM IN DNA BY USING MASS SPECTROSCOPY 审中-公开VERFAHREN ZUM NACHWEIS VON POLYMORPHISMUS IN DNA UNTER VERWENDUNG DER MASSENSPEKTROSKOPIE
公开(公告)号：EP1350851A1
公开(公告)日：2003-10-08
申请号：EP01271113.1
申请日：2001-12-12
发明人： INOKO, Hidetoshi , TAMIYA, Gen , NAKAJIMA, Kenji , KIMURA, Naoki , NAGASHIMA, Renpei, c/o CHUGAI SEIYAKU KABUSHIKI K. , MORIKAWA, Minoru, c/o CHUGAI SEIYAKU KABUSHIKI K. , OKAMOTO, Kouichi
CPC分类号： C12Q1/6872 , C12Q2565/518 , C12Q2535/131
摘要： In the detection of a genetic polymorphism using a mass spectrometer, a genomic DNA containing target polymorphism can be separated from a DNA sample and bound at the same time onto a platform by the following steps: binding an oligonucleotide that hybridizes with the genomic DNA containing the target polymorphism to the platform; and then applying the genomic DNA sample to the platform . Thus, a target polymorphism can be more efficiently detected. According to the method of the present invention, polymorphisms in a large number of specimens can be quickly and comprehensively detected.
摘要翻译： 在使用质谱仪的遗传多态性的检测中，可以从DNA样品中分离含有靶基因多态性的基因组DNA，并通过以下步骤同时结合到平台上：将与含有 目标多态性到平台; 然后将基因组DNA样品应用于平台。 因此，可以更有效地检测目标多态性。 根据本发明的方法，可以快速，全面地检测大量标本中的多态性。
-
公开(公告)号：EP4126956A1
公开(公告)日：2023-02-08
申请号：EP21778912.2
申请日：2021-03-30
发明人： ISHII, Shinya , KIMURA, Naoki , KODAMA, Tatsushi
-
3.发明授权
公开(公告)号：EP2130552B1
公开(公告)日：2016-06-15
申请号：EP08721318.7
申请日：2008-02-27
发明人： KIMURA, Naoki
IPC分类号： A61K39/395 , A61K49/00 , A61P9/14 , A61P35/00 , A61P43/00 , C07K16/18 , C12N15/09 , C12P21/08 , C07K16/30 , C07K16/28
CPC分类号： C07K16/28 , A61K47/6811 , A61K47/6817 , A61K47/6843 , A61K2039/505 , C07K16/30 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/77
-
公开(公告)号：EP1561759B1
公开(公告)日：2008-11-12
申请号：EP03751456.9
申请日：2003-10-10
CPC分类号： C07K16/2833 , A61K2039/505 , C07K14/70539 , C07K2317/34 , C07K2317/565 , C07K2317/626 , C07K2317/73
-
公开(公告)号：EP1561759A1
公开(公告)日：2005-08-10
申请号：EP03751456.9
申请日：2003-10-10
CPC分类号： C07K16/2833 , A61K2039/505 , C07K14/70539 , C07K2317/34 , C07K2317/565 , C07K2317/626 , C07K2317/73
摘要： To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. The results suggested that the 2D7 antigen is an HLA class I molecule. Based on this finding, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents.
摘要翻译： 为了鉴定2D7抗体的抗原，本发明人克隆了2D7抗原。 结果表明，2D7抗原是HLA I类分子。 基于该发现，本发明人检查了2D7抗体是否具有细胞死亡诱导活性。 当2D7抗体与另一种抗体交联时，观察到细胞核碎裂，表明诱导细胞死亡。 此外，发现2D7抗体的双抗体具有非常强的细胞死亡诱导活性，即使没有添加另一种抗体。 这些结果表明HLA识别抗体的小体抗体可以用作细胞死亡诱导剂。
-
6.发明公开PHARMACEUTICAL COMPOSITION CONTAINING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT 审中-公开用单克隆抗体抗HB-EGF活性药物成分
公开(公告)号：EP2468771A9
公开(公告)日：2014-01-08
申请号：EP10809728.8
申请日：2010-08-17
发明人： KIMURA, Naoki
IPC分类号： C07K16/22 , A61K39/395 , A61P35/00 , C12Q1/02
CPC分类号： C07K16/22 , C07K2317/24 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/57407 , G01N33/577
摘要： An anti-HB-EGF antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-HB-EGF antibody of the present invention. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the antibody of the present invention as an active ingredient, a method of treating cancer and a method of diagnosing cancer, which comprise the administration of the antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, uterine cervical cancer, breast cancer, bladder cancer, brain tumors, and hematological cancers.
-
公开(公告)号：EP1561759B9
公开(公告)日：2009-08-26
申请号：EP03751456.9
申请日：2003-10-10
CPC分类号： C07K16/2833 , A61K2039/505 , C07K14/70539 , C07K2317/34 , C07K2317/565 , C07K2317/626 , C07K2317/73
摘要： In order to identify an antigen to 2D7 antibody, a 2D7 antigen is cloned. As a result, it is indicated that the 2D7 antigen is an HLA class I molecule. Based on this finding, it is discussed whether the 2D7 antibody has an activity of inducing cell death or not. As a result, nuclear fragmentation is observed by further crosslinking the 2D7 antibody with another antibody, thereby indicating that cell death is induced. It is also clarified that a diabody of the 2D7 antibody has an extremely strong cell death-inducing activity even though no other antibody is added. These results point out that a degradation product of an antibody recognizing HLA is usable as a cell death-inducing agent.
-
公开(公告)号：EP3915581A1
公开(公告)日：2021-12-01
申请号：EP20745918.1
申请日：2020-01-24
发明人： NEZU, Junichi , KODAMA, Tatsushi , HOSHINO, Mayumi , KIMURA, Naoki , NAGANO, Kohji , KATO, Kuniyasu , YOKOTA, Yukari
摘要： In a non-limiting embodiment, isolated antibodies that bind to any of the following proteins are provided: XPR1, NOX1, MARVELD3 isoform 1, MARVELD3 isoform 2, SPINT2, MANSC1, SLC12A2, CDCP1, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, and TMPRSS4.
-
公开(公告)号：EP2388320B1
公开(公告)日：2017-02-15
申请号：EP09834850.1
申请日：2009-12-22
发明人： KAWAI, Shigeto , KIMURA, Naoki
IPC分类号： C07K16/30 , C07K16/40 , C07K16/46 , C12N15/09 , A61K39/395 , A61P35/00 , G01N33/574 , C12P21/08
CPC分类号： C07K16/30 , C07K16/28 , C07K16/40 , C07K2317/73 , C07K2317/732 , G01N33/57423 , G01N33/57438 , G01N33/57449
-
10.发明公开PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT 审中-公开具有抗HB-EGF抗体作为活性药物成分
公开(公告)号：EP3040347A3
公开(公告)日：2016-09-21
申请号：EP16152989.6
申请日：2007-10-19
发明人： KIMURA, Naoki
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/34 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/92
摘要： An anti-HB-EGF antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-HB-EGF antibody of the present invention. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the antibody of the present invention as an active ingredient, a method of treating cancer and a method of diagnosing cancer, which comprise the administration of the antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, uterine cervical cancer, breast cancer, bladder cancer, brain tumors, and hematological cancers.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.018 秒)
